Results

1–10 of 11 results for David S. Boyer

Anatomic Changes Following a Single Injection of AVD-104 in Patients With GA Secondary to AMD in the SIGLEC Study
David S. Boyer, MD
Annual Meeting Talks
2024
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Updates from the Field
2025
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Annual Meeting Talks
2022
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Updates from the Field
2022
Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME)
David S. Boyer, MD
Annual Meeting Talks
2020
Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study
David S. Boyer, MD
Updates from the Field
2021
Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials
David S. Boyer, MD
Updates from the Field
2021
The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses
David S. Boyer, MD
Annual Meeting Talks
2019
Effect of Baseline Ocular Characteristics on Vitreomacular Adhesion/Vitreomacular Traction Resolution With Ocriplasmin: ORBIT Study Subanalysis
David S. Boyer, MD
Annual Meeting Talks
2018
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017